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Introduction
Pembrolizumab is a humanized IgG4 antieprogrammed cell
death 1 (PD-1) antibody that is widely used in various malignancies.
According to most recent European Society for Medical Oncology
guidelines, pembrolizumab with or without chemotherapy is the
standard first-line treatment option in stage IV nonesmall-cell lung
cancer (NSCLC) patients without an actionable oncogenic driver.1
Consequently, a major group of patients is treated with this im-
mune checkpoint inhibitor that has significantly improved survival
rates for a subgroup of patients.2 Among these are patients with
comorbid conditions, of which clinical data on pembrolizumab
treatment are lacking because these patients are largely excluded
from clinical trials.3 This results in discrepancies between pem-
brolizumab registration and its application in daily practice.
Nephrotic syndrome is one of those comorbidities associated
with lung cancer of which the impact on efficacy and safety of
pembrolizumab therapy is unknown.1,4 Nephrotic syndrome is
characterized by severe proteinuria with hypoalbuminemia, hyper-
lipidemia, and peripheral edema,5 conditions that interfere with
monoclonal antibody pharmacokinetics. Proteinuria is known to
cause renal excretion of therapeutic monoclonal antibodies, and
hypoalbuminemia is reported to be correlated with an increase in
monoclonal antibody clearance by enhanced protein turnover.6
Pharmacokinetic measurements will give more insight in the
impact of these conditions on immunotherapy exposure. Addi-
tionally, these findings underline the importance to report on
treatment of patients in this setting to achieve safe and effective
oncologic treatment.
We present a case describing the use, exposure, and outcome of
pembrolizumab therapy to treat a case ofNSCLCwith proteinuria and
severe hypoalbuminemia due to paraneoplastic nephrotic syndrome.
Case Report
A 55-year-old male patient was referred to our medical center for
first-line immunotherapy treatment to treat a programmed death
ligand 1 (PD-L1)-high stage IVA (cTxN3M1a) adenocarcinoma of
Clinical Practice Points
 Discrepancies in pembrolizumab registration and its
application in daily practice exist thanks to the sparse
clinical data in specific patient populations.
 We report a case of nonesmall-cell lung cancer with
paraneoplastic nephrotic syndrome in which
therapeutic exposure and response were obtained
despite renal loss of pembrolizumab.
 Determination of pembrolizumab serum concentra-
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the lung. PD-L1 expression was assessed by immunohistochemistry
using a laboratory-developed technique based on detection of the
primary antibody with a polymer type detection system and suc-
cessfully cross-validated against the PD-L1 immunohistochemistry
22C3 pharmDx assay (Agilent Technologies, Santa Clara, CA),
resulting in a PD-L1 tumor proportion score of 90%. Next-
generation sequencing did not reveal any options for first-line tar-
geted therapy: there were no mutations in EGFR, KRAS, BRAF,
ERBB2, or MET. Fluorescence in-situ hybridization (FISH) ruled
out the presence of ALK, ROS1, or RET translocation. A significant
amplification of MET (7 copies) was detected with FISH, which
might be an option for treatment in a clinical trial after standard-of-
care options have failed.
Approximately 4 months before tumor diagnosis, the patient
experienced severe edema in his lower limbs and the lower parts of
his abdomen. A peripheral arterial occlusion in the left leg was
diagnosed, for which he underwent a percutaneous transluminal
angioplasty and received antiplatelet treatment. The edema was
attributed to vascular problems. During the analysis leading to the
diagnosis of NSCLC, he experienced a deep venous thrombosis in
his left leg, for which treatment with low-weight molecular heparin
was initiated. A week after this event, radiologic and pathologic
analysis established the diagnosis of metastasized NSCLC. He was
referred to our hospital for treatment, where he was found to have
pleural effusion, weight gain (w10 kg), dyspnea, cough, and
thoracic pain. Complaints had greatly progressed in the last 3 weeks,
leading to a severe deterioration of his fitness, with an Eastern
Cooperative Oncology Group performance status (ECOG PS) of 2.
Pembrolizumab treatment was discussed and initiated 2 weeks later,
after molecular analysis failed to show options for targeted therapy.
At this point in time, he was clinically diagnosed with nephrotic
syndrome, with widespread edema, proteinuria (maximum 19.20 g/
L), and hypoalbuminemia (lowest albumin 5 g/L; normal range, 35-
50 g/L). Results for laboratory measurements over time are pre-
sented in Table 1. The ratio of IgG and transferrin clearance, the
selectivity index, was increased (0.26, normal range: < 0.10),
indicating the presence of a severe defect of the glomerular capillary
filter. Serum antiephospholipase A2 receptor and anti-THSD7A
testing results were negative. A diagnosis of primary membranous
nephropathy was thus considered unlikely, making a paraneoplastic
syndrome the most probable underlying cause. Because the mar-
ginal performance status was mainly attributed to this paraneoplastic
syndrome, treatment with first-line immunotherapy was started:
200 mg pembrolizumab intravenously every 3 weeks. Nephrotic
syndrome was managed symptomatically, and edema decreased
dramatically after initiation of amiloride. A kidney biopsy was
initially not performed because of the high risk for hemorrhagic
complications due to anticoagulant therapy, which could not be
interrupted in the light of recent thromboembolic events and the
high risk of recurrence. Moreover, the stable glomerular filtration
rate and the absence of therapeutic consequences made histopath-
ologic confirmation clinically less relevant.
Renal function loss and progressive hypoalbuminemia concurrent
with radiologic evidence of NSCLC progression 12 months after the
last pembrolizumab administration prompted us to perform a renal
biopsy. Histopathology revealed a stage 2-3 membranous ne-
phropathy, concordant with a paraneoplastic etiology.
Urinary loss of immunoglobulins in the setting of severe
nephrotic syndrome raised concerns regarding pembrolizumab’s
therapeutic efficacy.6 To evaluate this, serum and urine pem-
brolizumab levels were determined by enzyme-linked immunosor-
bent assay according to Pluim et al7 (Table 1). Four, 6, and 9 weeks
after the start of pembrolizumab treatment, serum trough concen-
trations (Cmin) were 14.8 mg/mL, 78.8 mg/mL, and 73.1 mg/mL,
respectively. Pembrolizumab peak plasma concentration (Cmax) was
307 mg/mL six weeks after first administration. Urine pem-
brolizumab levels were assessed 4 and 6 weeks after first pem-
brolizumab administration and were 2.41 mg/mL and 1.63 mg/mL,
respectively.
The patient’s disease responded to immunotherapy treatment
with a partial radiologic response: a maximum decrease of 33% in
target lesion size according to Response Evaluation Criteria in Solid
Tumors (RECIST) after 6 cycles of pembrolizumab treatment. His
ECOG PS improved to 0. The edema resolved, and parameters
associated with severity of the paraneoplastic nephrotic syndrome
improved. The last available measurements during a stable disease
state approximately 9 months after the first pembrolizumab
administration showed a normal serum creatinine level (79 mmol/
L), a serum albumin level that improved to 17 g/L, and a urine
protein loss that decreased to 2.22 g/L. Pembrolizumab treatment
was discontinued after 7 cycles because of therapy-related grade 4
neutropenia according to Common Terminology Criteria for
Adverse Events (CTCAE) 4.03. More than 9 months (286 days)
after the last pembrolizumab administration, the patient was seen
with a tumor response that was characterized as stable disease ac-
cording to RECIST.
Table 1 Results for Serum and Urine Drug Concentrations and Clinical Parameters for Nephrotic Syndrome by Time
Result
Time Since Start of Treatment
0 Weeks 3 Weeks 6 Weeks 9 Weeks 12 Weeks 24 Weeks 36 Weeks
Serum trough concentration pembrolizumab (mg/mL) 14.8 78.8 73.1
Serum peak concentration pembrolizumab (mg/mL) 307
Urine concentration pembrolizumab (mg/mL) 2.41 1.63
Serum creatinine (mmol/L; normal range 60-110 mmol/L) 90 121 104 92 90 83 79
Serum albumin (g/L; normal range 35-50 g/L) 7 6 5 6 8 10 17
Urine protein (g/L) 19.20 15.72 17.48 2.22
Protein creatinine ratio (g/10 mmol; normal
range < 10 g/10 mmol)
13.08 12.22 5.00
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Informed consent for this case report was obtained from the
patient.
Discussion
Despite severe hypoalbuminemia and significant renal pem-
brolizumab loss in our patient, therapeutic pembrolizumab serum
levels and a clinical response to therapy were observed. The median
expected Cmin for pembrolizumab at a dose of 200 mg every 3
weeks is 27.6 mg/mL (10%-90% percentile, 14.9-46.2 mg/mL).8
Early clinical studies of pembrolizumab used dosing strategies of 2
mg/kg every 3 weeks to 10 mg/kg every 2 weeks. It was found that
maximum PD-1 inhibition by pembrolizumab is already achieved at
doses of 1 mg/kg and higher, associated with a Cmin in the range of
1-10 mg/mL.9,10 Our patient obtained Cmin levels above this con-
centration. The measured serum concentrations of our patient also
fell well below expected concentrations at the highest explored
dosage level in clinical studies that was found to be safe and tolerable
(10%-90% percentile: 111.8-325.3 mg/mL and 315.9-599.9 mg/
mL for Cmin and Cmax, respectively).
8 Obtaining therapeutic
exposure was confirmed by the radiologic and clinical response and
a significant improvement of the nephrotic syndrome.
In the absence of a renal condition, there is no renal loss of mono-
clonal antibodies because of impermeability of the renal glomeruli for
molecules with high molecular mass.11 However, proteinuria as occurs
in paraneoplastic nephrotic syndrome is known todecrease the systemic
exposure to therapeutic monoclonal antibodies.6 Additionally, serum
albumin concentrations have been reported to be inversely correlated
with clearance of monoclonal antibodies through endogenous catabo-
lism.6 Hypoalbuminemia is associated with increased protein turnover
and thus increased clearance and reduced systemic exposure to thera-
peutically administered monoclonal antibodies.6 Urine pem-
brolizumab concentrations of our patient confirmed this.
Importantly, treatment with immune checkpoint inhibitors is
associated with adverse renal effects, with tubulointerstitial nephritis
being the predominant lesion.12 Several reports have also described
nephrotic syndrome in association with immune checkpoint in-
hibitor treatment.13,14 However, on the basis of immunohisto-
chemistry and molecular analysis, pembrolizumab was considered
the best treatment option for our patient. Pembrolizumab treatment
resulted in resolution of the nephrotic syndrome in parallel with the
oncologic response. Our case thus demonstrates that antiePD-1
treatment should not be withheld from patients with poor perfor-
mance status due to suspected paraneoplastic nephrotic syndrome.
To our knowledge, there have been no previous reports similar to
our case, where treatment with a monoclonal antibody in a patient
with paraneoplastic nephrotic syndrome and both severe protein
and monoclonal antibody loss resulted in therapeutic exposure and
treatment response. A previous case report of a patient with para-
neoplastic nephrotic syndrome in lung cancer described remission of
nephrotic syndrome after adjuvant chemotherapy after resection.15
The antiePD-1 monoclonal antibody nivolumab was adminis-
tered at recurrence of progression to metastatic disease. This resulted
in complete remission. However, the nephrotic syndrome had
already been resolved at the start of immunotherapy.
With this report,wehope to contribute tofilling the information gap
between clinical practice and clinical study data on the safety and ef-
ficacy of pembrolizumab, as patients with concomitant abnormalities
or ECOG PS  2 are underrepresented in clinical studies.2 Our case
underlines the need for widening the inclusion criteria of clinical trials
for novel anticancer drugs to better represent daily clinical reality.
Furthermore, systematic collection and analysis of real-world data for
approved drugs should be used to confirm the external validity of
clinical trials, as has been previously advocated.16-18
Our case demonstrates the importance of an individual approach
to oncologic treatment. On the basis of guidelines and low per-
formance status, one might consider withholding this pem-
brolizumab treatment in this case. Our patient received therapeutic
drug exposure and had disease that significantly responded to
therapy. Therefore, clinicians may consider immunotherapy as a
suitable anticancer treatment option in patients with paraneoplastic
nephrotic syndrome. Determination of serum concentrations of
monoclonal antibodies may help to ascertain whether therapeutic
exposure is attained and help guide individual dose adjustments in
case of severe proteinuria and hypoalbuminemia.
Conclusion
Despite renal loss of pembrolizumab in this NSCLC patient with
paraneoplastic nephrotic syndrome, immunotherapy treatment
resulted in therapeutic drug exposure and both radiologic and
clinical response. As this is the first report in its kind, further studies
to confirm efficacy of immunotherapy treatment in this setting are
required. Determination of pembrolizumab serum levels can be
helpful to establish if therapeutic exposure is attained in case of
severe proteinuria and hypoalbuminemia. Clinicians should be
aware that immunotherapy may still be an option in patients with
these conditions, even with ECOG PS > 1. Despite reported renal
adverse events of PD-1 inhibitors, including onset of nephrotic
syndrome, our case report demonstrates that pembrolizumab can be
an effective (palliative) treatment for patients with a PD-L1ehigh
malignancy and paraneoplastic nephrotic syndrome.
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